FDA warns about treating COVID-19 with unproven drugs

FDA warns about treating COVID-19 with unproven drugs

(HealthDay)—Malaria drugs touted by some as potential "game changers" against COVID-19 are actually too dangerous for general use, the U.S. Food and Drug Administration warned Americans on Friday.

According to the FDA, studies have shown that the drugs chloroquine and hydroxychloroquine may trigger potentially fatal heart rhythm problems in COVID-19 patients. The agency also said that it is aware of a rise in outpatient prescriptions for the two drugs and said that and patients need to be aware of the risks associated with the drugs.

"Hydroxychloroquine and chloroquine have not been shown to be safe and effective for treating or preventing COVID-19. They are being studied in clinical trials for COVID-19, and we authorized their temporary use during the COVID-19 pandemic for treatment of the virus in hospitalized patients when are not available, or participation is not feasible," the FDA explained in a news release. "Hydroxychloroquine and chloroquine can cause such as QT interval prolongation and a dangerously rapid heart rate called ventricular tachycardia."

"These risks may increase when these medicines are combined with other medicines known to prolong the QT interval, including the antibiotic azithromycin, which is also being used in some COVID-19 patients without FDA approval for this condition. Patients who also have other health issues such as heart and kidney disease are likely to be at increased risk of these heart problems when receiving these medicines," the FDA said.


Explore further

Follow the latest news on the coronavirus (COVID-19) outbreak

More information: More Information

Copyright © 2020 HealthDay. All rights reserved.

Citation: FDA warns about treating COVID-19 with unproven drugs (2020, April 27) retrieved 5 December 2020 from https://medicalxpress.com/news/2020-04-fda-covid-unproven-drugs.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
5 shares

Feedback to editors

User comments